echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Nature: A new type of CAR-T cells that can target cancer driver factors that could not be targeted before

    Nature: A new type of CAR-T cells that can target cancer driver factors that could not be targeted before

    • Last Update: 2021-11-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Researchers at the Children’s Hospital of Philadelphia (CHOP) have made a breakthrough in the treatment of aggressive solid cancers.


    This discovery, published in the journal Nature, opens the door to the use of immunotherapy to treat a wider range of cancers and the application of each therapy to a larger proportion of the population


    "This research is very exciting because it improves the possibility of targeting very specific tumor molecules, expanding the cancers that can be treated with immunotherapy and the patient population that can benefit," a researcher and paper in the Maris Laboratory at the Children's Hospital of Philadelphia First author Dr.


    The development of CAR-T cell-based cancer immunotherapy marks a breakthrough in the treatment of leukemia, but this approach has not yet made significant progress in the treatment of solid tumors, at least in part due to the lack of tumor-specific targets


    Neuroblastoma is an aggressive, aggressive childhood cancer that is driven by changes in gene expression and promotes uncontrolled tumor growth


    Despite these obstacles, the researchers hypothesized that some peptides on the surface of neuroblastoma cells are derived from proteins that are essential for tumor growth and survival and can be targeted by synthetic CARs


    To this end, researchers isolated MHC molecules from neuroblastoma cells and determined which peptides were present and in what abundance


    Using this multi-omics method, the researchers identified an unmutated neuroblastoma peptide from PHOX2B, which is a neuroblastoma-dependent gene and transcription regulator that has been previously identified and described in CHOP


    In further research, the research team tested PC-CARs on mice and found that this treatment can completely and targetedly eliminate neuroblastoma


    "We are excited about this work because it allows us to now track basic cancer drivers that were considered'unavailable drugs' in the past


    Original search:

    Yarmarkovich et al.



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.